NKGen Biotech reports Phase 1 troculeucel data showing 100% stable or improved cognition in moderate Alzheimer’s disease

Reuters03-23

NKGen Biotech reports Phase 1 troculeucel data showing 100% stable or improved cognition in moderate Alzheimer’s disease

NKGen reported combined data from two completed open-label Phase 1 trials of troculeucel in Alzheimer’s disease that were presented at AD/PD 2026.
In a pooled analysis of moderate Alzheimer’s patients at the 3-month assessment (n=6), 100% were stable or improved across MCID thresholds and no cognitive decline was observed.
Higher doses of 4-6 billion cells were associated with more frequent clinically meaningful improvements, and 50% of patients moved from moderate to mild range on CDR-SB at three months.
Among two patients followed for up to 12 months, cognitive improvements were maintained during treatment.
Exploratory plasma GFAP analyses showed baseline correlations with CDR-SB (r=0.6, p=0.044) and ADCOMS (r=0.64, p=0.03).

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230805PRIMZONEFULLFEED9670433) on March 23, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2621870332?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-23 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2621870332","market":"us","top_or_hot":-1,"title":"NKGen Biotech reports Phase 1 troculeucel data showing 100% stable or improved cognition in moderate Alzheimer’s disease","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NKGen Biotech reports Phase 1 troculeucel data showing 100% stable or improved cognition in moderate Alzheimer’s disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          NKGen reported combined data from two completed open-label Phase 1 trials of troculeucel in Alzheimer’s disease that were presented at AD/PD 2026.\n        </li>\n<li>\n          In a pooled analysis of moderate Alzheimer’s patients at the 3-month assessment (n=6), 100% were stable or improved across MCID thresholds and no cognitive decline was observed.\n        </li>\n<li>\n          Higher doses of 4-6 billion cells were associated with more frequent clinically meaningful improvements, and 50% of patients moved from moderate to mild range on CDR-SB at three months.\n        </li>\n<li>\n          Among two patients followed for up to 12 months, cognitive improvements were maintained during treatment.\n        </li>\n<li>\n          Exploratory plasma GFAP analyses showed baseline correlations with CDR-SB (r=0.6, p=0.044) and ADCOMS (r=0.64, p=0.03).\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NKGN\">Nkgen Biotech</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230805PRIMZONEFULLFEED9670433) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>NKGen Biotech reports Phase 1 troculeucel data showing 100% stable or improved cognition in moderate Alzheimer’s disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNKGen Biotech reports Phase 1 troculeucel data showing 100% stable or improved cognition in moderate Alzheimer’s disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-23 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      NKGen Biotech reports Phase 1 troculeucel data showing 100% stable or improved cognition in moderate Alzheimer’s disease\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          NKGen reported combined data from two completed open-label Phase 1 trials of troculeucel in Alzheimer’s disease that were presented at AD/PD 2026.\n        </li>\n<li>\n          In a pooled analysis of moderate Alzheimer’s patients at the 3-month assessment (n=6), 100% were stable or improved across MCID thresholds and no cognitive decline was observed.\n        </li>\n<li>\n          Higher doses of 4-6 billion cells were associated with more frequent clinically meaningful improvements, and 50% of patients moved from moderate to mild range on CDR-SB at three months.\n        </li>\n<li>\n          Among two patients followed for up to 12 months, cognitive improvements were maintained during treatment.\n        </li>\n<li>\n          Exploratory plasma GFAP analyses showed baseline correlations with CDR-SB (r=0.6, p=0.044) and ADCOMS (r=0.64, p=0.03).\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/NKGN\">Nkgen Biotech</a> Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230805PRIMZONEFULLFEED9670433) on March 23, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NKGN","symbol_name":"NKGen Biotech Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL9HkLjR:1","article_id":"2621870332","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2621870332","pubTimestamp":1774267519,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"NKGen reported combined data from two completed open-label Phase 1 trials of troculeucel in Alzheimer’s disease that were presented at AD/PD 2026.In a pooled analysis of moderate Alzheimer’s patients at the 3-month assessment (n=6), 100% were stable or improved across MCID thresholds and no cognitive decline was observed.Higher doses of 4-6 billion cells were associated with more frequent clinically meaningful improvements, and 50% of patients moved from moderate to mild range on CDR-SB at three months.Among two patients followed for up to 12 months, cognitive improvements were maintained during treatment.Exploratory plasma GFAP analyses showed baseline correlations with CDR-SB  and ADCOMS .","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NKGN":"NKGen Biotech Inc.","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","NDAQ":"纳斯达克OMX交易所","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","BK4588":"碎股","BK4112":"金融交易所和数据","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","BK4585":"ETF&股票定投概念","BK4139":"生物科技"},"translate_title":"NKGen Biotech报告1期troculeucel数据显示中度阿尔茨海默病患者认知100%稳定或改善","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"NKGN":0.9},"content_text":"NKGen Biotech reports Phase 1 troculeucel data showing 100% stable or improved cognition in moderate Alzheimer’s disease\n    \n\n\n          NKGen reported combined data from two completed open-label Phase 1 trials of troculeucel in Alzheimer’s disease that were presented at AD/PD 2026.\n        \n\n          In a pooled analysis of moderate Alzheimer’s patients at the 3-month assessment (n=6), 100% were stable or improved across MCID thresholds and no cognitive decline was observed.\n        \n\n          Higher doses of 4-6 billion cells were associated with more frequent clinically meaningful improvements, and 50% of patients moved from moderate to mild range on CDR-SB at three months.\n        \n\n          Among two patients followed for up to 12 months, cognitive improvements were maintained during treatment.\n        \n\n          Exploratory plasma GFAP analyses showed baseline correlations with CDR-SB (r=0.6, p=0.044) and ADCOMS (r=0.64, p=0.03).\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nkgen Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603230805PRIMZONEFULLFEED9670433) on March 23, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2621870332","isCrawlerRequest":true}